JP6534389B2 - Ｓｈｐ２の活性を阻害するためのｎ−アザスピロシクロアルカン置換ｎ−ヘテロアリール化合物および組成物 - Google Patents

Ｓｈｐ２の活性を阻害するためのｎ−アザスピロシクロアルカン置換ｎ−ヘテロアリール化合物および組成物 Download PDF

Info

Publication number
JP6534389B2
JP6534389B2 JP2016546839A JP2016546839A JP6534389B2 JP 6534389 B2 JP6534389 B2 JP 6534389B2 JP 2016546839 A JP2016546839 A JP 2016546839A JP 2016546839 A JP2016546839 A JP 2016546839A JP 6534389 B2 JP6534389 B2 JP 6534389B2
Authority
JP
Japan
Prior art keywords
amino
mmol
alkyl
substituted
azaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016546839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502993A5 (cg-RX-API-DMAC7.html
JP2017502993A (ja
Inventor
ヒウ−トゥン チェン，クリスティーン
ヒウ−トゥン チェン，クリスティーン
チェン，ツァオリャン
ドレ，マイケル
ガルシア フォルタネット，ジョルジ
ガルシア フォルタネット，ジョルジ
カルキ，ラジェシュ
充典 加藤
充典 加藤
ジェイ． ラマーシュ，マシュー
ジェイ． ラマーシュ，マシュー
ブラス ペレズ，ローレンス
ブラス ペレズ，ローレンス
ダグラス スミス，トロイ
ダグラス スミス，トロイ
ウィリアムス，サラ
ウィリアム ギラルデス，ジョン
ウィリアム ギラルデス，ジョン
トゥーレ，バカリ−バリー
センドジク，マーティン
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2017502993A publication Critical patent/JP2017502993A/ja
Publication of JP2017502993A5 publication Critical patent/JP2017502993A5/ja
Application granted granted Critical
Publication of JP6534389B2 publication Critical patent/JP6534389B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2016546839A 2014-01-17 2015-01-16 Ｓｈｐ２の活性を阻害するためのｎ−アザスピロシクロアルカン置換ｎ−ヘテロアリール化合物および組成物 Active JP6534389B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461928754P 2014-01-17 2014-01-17
US61/928,754 2014-01-17
US201461991129P 2014-05-09 2014-05-09
US61/991,129 2014-05-09
PCT/IB2015/050345 WO2015107495A1 (en) 2014-01-17 2015-01-16 N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2

Publications (3)

Publication Number Publication Date
JP2017502993A JP2017502993A (ja) 2017-01-26
JP2017502993A5 JP2017502993A5 (cg-RX-API-DMAC7.html) 2018-02-22
JP6534389B2 true JP6534389B2 (ja) 2019-06-26

Family

ID=52462974

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016546839A Active JP6534389B2 (ja) 2014-01-17 2015-01-16 Ｓｈｐ２の活性を阻害するためのｎ−アザスピロシクロアルカン置換ｎ−ヘテロアリール化合物および組成物

Country Status (42)

Country Link
US (6) US10077276B2 (cg-RX-API-DMAC7.html)
EP (1) EP3094628B1 (cg-RX-API-DMAC7.html)
JP (1) JP6534389B2 (cg-RX-API-DMAC7.html)
KR (2) KR102501558B1 (cg-RX-API-DMAC7.html)
CN (1) CN105916845B (cg-RX-API-DMAC7.html)
AP (1) AP2016009299A0 (cg-RX-API-DMAC7.html)
AR (1) AR100033A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015207757B8 (cg-RX-API-DMAC7.html)
BR (1) BR112016016432B1 (cg-RX-API-DMAC7.html)
CA (1) CA2935695C (cg-RX-API-DMAC7.html)
CL (1) CL2016001790A1 (cg-RX-API-DMAC7.html)
CR (2) CR20200617A (cg-RX-API-DMAC7.html)
CU (1) CU24424B1 (cg-RX-API-DMAC7.html)
CY (1) CY1121155T1 (cg-RX-API-DMAC7.html)
DK (1) DK3094628T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2016000177A (cg-RX-API-DMAC7.html)
EA (1) EA031573B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP16067692A (cg-RX-API-DMAC7.html)
ES (1) ES2695242T3 (cg-RX-API-DMAC7.html)
GT (1) GT201600147A (cg-RX-API-DMAC7.html)
HR (1) HRP20181832T1 (cg-RX-API-DMAC7.html)
HU (1) HUE039869T2 (cg-RX-API-DMAC7.html)
IL (1) IL246436B (cg-RX-API-DMAC7.html)
JO (1) JO3517B1 (cg-RX-API-DMAC7.html)
LT (1) LT3094628T (cg-RX-API-DMAC7.html)
MA (1) MA39282B1 (cg-RX-API-DMAC7.html)
MX (1) MX356895B (cg-RX-API-DMAC7.html)
MY (1) MY176357A (cg-RX-API-DMAC7.html)
NI (1) NI201600101A (cg-RX-API-DMAC7.html)
NZ (1) NZ721598A (cg-RX-API-DMAC7.html)
PE (1) PE20170011A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016501336B1 (cg-RX-API-DMAC7.html)
PL (1) PL3094628T3 (cg-RX-API-DMAC7.html)
PT (1) PT3094628T (cg-RX-API-DMAC7.html)
RS (1) RS57757B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201605272SA (cg-RX-API-DMAC7.html)
SI (1) SI3094628T1 (cg-RX-API-DMAC7.html)
SV (1) SV2016005245A (cg-RX-API-DMAC7.html)
TN (1) TN2016000268A1 (cg-RX-API-DMAC7.html)
TW (1) TWI657083B (cg-RX-API-DMAC7.html)
UY (1) UY35957A (cg-RX-API-DMAC7.html)
WO (1) WO2015107495A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021130662A (ja) * 2015-06-19 2021-09-09 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357184B2 (en) * 2012-06-21 2019-07-23 Globus Medical, Inc. Surgical tool systems and method
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
ES2935352T3 (es) 2013-01-29 2023-03-06 Aptinyx Inc Moduladores de receptores NMDA de espiro-lactama y sus usos
CN105899491B (zh) 2014-01-17 2019-04-02 诺华股份有限公司 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
JP6473457B2 (ja) 2014-01-17 2019-02-20 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物
JP2018509448A (ja) * 2015-03-25 2018-04-05 ノバルティス アーゲー 組合せ医薬
JP6718889B2 (ja) * 2015-06-19 2020-07-08 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
CN105503725B (zh) * 2015-12-30 2018-03-27 天津药明康德新药开发有限公司 一种叔丁基1‑羟基‑8‑氮杂螺烷[4,5]葵烷‑8‑羧酸酯的制备方法
JP7044375B2 (ja) * 2016-05-31 2022-03-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｐｔｐｎ１１の複素環式阻害剤
KR20230109185A (ko) * 2016-06-07 2023-07-19 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CN114057689A (zh) * 2016-06-14 2022-02-18 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
TN2019000010A1 (en) * 2016-07-12 2020-07-15 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
CA3031563C (en) 2016-08-01 2023-12-05 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
KR102503590B1 (ko) 2016-08-01 2023-02-24 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
EA201990424A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
TWI848901B (zh) 2016-10-24 2024-07-21 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
EP3568204B1 (en) 2017-01-10 2023-08-30 Novartis AG Pharmaceutical combination comprising an alk inhibitor and an shp2 inhibitor
CA3051054A1 (en) * 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
CA3051206A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Bicyclic compounds as allosteric shp2 inhibitors
PT3601239T (pt) * 2017-03-23 2024-10-24 Jacobio Pharmaceuticals Co Ltd Novos derivados heterocíclicos úteis como inibidores de shp2
WO2018218133A1 (en) 2017-05-26 2018-11-29 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
GB2577436B (en) * 2017-06-20 2024-11-27 Control Components Multi-stage, multi-path rotary disc valve
AU2018328273A1 (en) 2017-09-07 2020-03-12 Revolution Medicines, Inc. SHP2 inhibitor compositions and methods for treating cancer
CN118684652A (zh) * 2017-09-11 2024-09-24 克鲁松制药公司 SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
EP3687997A1 (en) 2017-09-29 2020-08-05 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
RU2020115095A (ru) 2017-10-12 2021-11-12 Революшн Медсинз, Инк. Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2
TWI697490B (zh) * 2017-12-06 2020-07-01 大陸商北京加科思新藥研發有限公司 用於作為shp2抑制劑之新穎雜環衍生物
MX2020006273A (es) 2017-12-15 2020-09-14 Revolution Medicines Inc Compuestos policiclicos como inhibidores alostericos de shp2.
WO2019152454A1 (en) * 2018-01-30 2019-08-08 Research Development Foundation Shp2 inhibitors and methods of use thereof
SG11202007256PA (en) 2018-01-31 2020-08-28 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
AU2019222026B2 (en) * 2018-02-13 2022-05-12 Shanghai Blueray Biopharma Co., Ltd. Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
CN110156786B (zh) * 2018-02-13 2022-06-03 青煜医药研发(上海)有限公司 嘧啶并环化合物及其制备方法和应用
US20200392161A1 (en) 2018-02-21 2020-12-17 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
MX2020008754A (es) 2018-03-02 2020-12-07 Otsuka Pharma Co Ltd Compuestos farmaceuticos.
WO2019183364A1 (en) 2018-03-21 2019-09-26 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
JP7265275B2 (ja) 2018-03-21 2023-04-26 スージョウ プーヘー バイオファーマ カンパニー リミテッド Ｓｈｐ２阻害剤およびその使用
AU2019240299B2 (en) * 2018-03-21 2023-06-22 D.E. Shaw Research, Llc SHP2 phosphatase inhibitors and methods of use thereof
JP2021521155A (ja) * 2018-04-10 2021-08-26 レヴォリューション・メディスンズ，インコーポレイテッド Ｓｈｐ２阻害剤組成物、癌を処置するための方法、およびｓｈｐ変異を有する対象を特定するための方法
IL300091A (en) 2018-05-01 2023-03-01 Revolution Medicines Inc C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
KR102611661B1 (ko) * 2018-05-02 2023-12-08 나비레 파르마, 인코퍼레이티드 Ptpn11의 치환된 헤테로사이클릭 억제제
CN116003321A (zh) * 2018-05-09 2023-04-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
US12037345B2 (en) 2018-07-24 2024-07-16 Taiho Pharmaceutical Co., Ltd. Heterobicyclic compounds for inhibiting the activity of SHP2
AU2019319971B2 (en) 2018-08-10 2024-11-28 Navire Pharma, Inc. 6-(4-amino-3-methyl-2-oxa-8-azaspiro(4.5)decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
FI3853234T3 (fi) 2018-09-18 2025-07-28 Nikang Therapeutics Inc Fuusioituja trisyklisiä rengasjohdannaisia SRC-homologia-2-fosfataasin estäjinä
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
JP7386855B2 (ja) * 2018-09-29 2023-11-27 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物及び組成物の製造
BR112021005606A2 (pt) 2018-09-29 2021-06-22 Novartis Ag processo de produção de um composto para inibir a atividade de shp2
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
TW202028183A (zh) * 2018-10-10 2020-08-01 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
ES2947464T3 (es) 2018-10-17 2023-08-09 Array Biopharma Inc Inhibidores de la proteína tirosina fosfatasa
CN117143079A (zh) * 2018-11-06 2023-12-01 上海奕拓医药科技有限责任公司 一种螺芳环化合物及其应用
CN111153899B (zh) * 2018-11-08 2023-12-01 四川科伦博泰生物医药股份有限公司 一种取代吡啶化合物、其制备方法和用途
CN113272303B (zh) 2018-11-30 2024-09-17 上海拓界生物医药科技有限公司 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CA3112129A1 (en) 2018-12-05 2020-06-11 Mirati Therapeutics, Inc. Combination therapies
CN113316574B (zh) * 2019-01-31 2024-01-30 贝达药业股份有限公司 Shp2抑制剂及其应用
JP7572958B2 (ja) * 2019-02-12 2024-10-24 ノバルティス アーゲー Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ
MX2021009563A (es) 2019-02-12 2021-09-08 Novartis Ag Combinacion farmaceutica que comprende tno155 y ribociclib.
EP3923940B1 (en) * 2019-02-12 2025-12-03 Novartis AG Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
CN111647000B (zh) * 2019-03-04 2021-10-12 勤浩医药（苏州）有限公司 吡嗪类衍生物及其在抑制shp2中的应用
WO2020181283A1 (en) 2019-03-07 2020-09-10 Merck Patent Gmbh Carboxamide-pyrimidine derivatives as shp2 antagonists
AU2020251841B2 (en) 2019-04-02 2025-01-30 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
AU2020271838A1 (en) * 2019-04-08 2021-08-19 Merck Patent Gmbh Pyrimidinone derivatives as SHP2 antagonists
EP4306529A3 (en) 2019-05-13 2024-04-10 Relay Therapeutics, Inc. Fgfr inhibitors and methods of use thereof
EP3980128A1 (en) * 2019-06-07 2022-04-13 Revolution Medicines, Inc. Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
CN113840603B (zh) 2019-06-28 2024-08-13 上海拓界生物医药科技有限公司 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN111704611B (zh) * 2019-07-25 2022-01-14 上海凌达生物医药有限公司 一类芳基螺环类shp2抑制剂化合物、制备方法和用途
CN112300160A (zh) * 2019-08-01 2021-02-02 上海奕拓医药科技有限责任公司 一种螺芳环化合物、其制备及应用
EP3772513A1 (en) * 2019-08-09 2021-02-10 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Shp2 inhibitors
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
US11890281B2 (en) 2019-09-24 2024-02-06 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of making and using the same
MX2022005525A (es) 2019-11-08 2022-06-08 Revolution Medicines Inc Compuestos de heteroarilo bicíclicos y usos de estos.
CN114761394B (zh) * 2020-01-16 2024-03-29 浙江海正药业股份有限公司 吡啶或嘧啶类衍生物及其制备方法和用途
CN113135910A (zh) 2020-01-19 2021-07-20 北京诺诚健华医药科技有限公司 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用
US20230090389A1 (en) 2020-02-28 2023-03-23 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor
TW202144334A (zh) * 2020-04-03 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 含氮雜芳類衍生物游離鹼的晶型
CN113493440B (zh) * 2020-04-03 2024-08-23 上海翰森生物医药科技有限公司 含氮杂芳类衍生物的盐及其晶型
WO2021218755A1 (zh) * 2020-04-30 2021-11-04 贝达药业股份有限公司 Shp2抑制剂及其组合物和应用
AU2021267213B2 (en) 2020-05-08 2023-11-30 Novartis Ag Pharmaceutical combination comprising TNO155 and nazartinib
WO2021236775A1 (en) * 2020-05-19 2021-11-25 The Regents Of The University Ofmichigan Small molecule degraders of shp2 protein
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
CN115734966B (zh) * 2020-06-12 2025-07-18 石药集团中奇制药技术（石家庄）有限公司 杂环化合物及其用途
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
CN115667239B (zh) 2020-06-22 2025-11-18 四川科伦博泰生物医药股份有限公司 取代吡嗪类化合物，包含其的药物组合物及其用途
WO2022006780A1 (en) * 2020-07-08 2022-01-13 Novartis Ag Manufacture of compounds and compositions for inhibiting activity of shp2
ES3040751T3 (en) 2020-07-08 2025-11-04 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of shp2
US20230339882A1 (en) * 2020-07-24 2023-10-26 Betta Pharmaceuticals Co., Ltd. Shp2 inhibitor and composition and application thereof
US20250195521A1 (en) 2020-09-03 2025-06-19 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
CN117683049A (zh) 2020-09-15 2024-03-12 锐新医药公司 作为ras抑制剂以治疗癌症的吲哚衍生物
WO2022063190A1 (zh) * 2020-09-23 2022-03-31 南京明德新药研发有限公司 吡嗪硫联苯基类化合物及其应用
TW202233625A (zh) 2020-11-18 2022-09-01 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法
EP4039685A1 (en) 2021-02-08 2022-08-10 Irbm S.P.A. Azabicyclic shp2 inhibitors
AU2022244941B2 (en) * 2021-03-23 2024-08-01 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Heterocycle substituted ketone derivative, and composition and medicinal use thereof
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
CN117083285A (zh) * 2021-03-31 2023-11-17 南京明德新药研发有限公司 一系列含Se的吡嗪类化合物及其应用
EP4067358A1 (en) 2021-04-02 2022-10-05 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2022235822A1 (en) 2021-05-05 2022-11-10 Huabio International, Llc Shp2 inhibitor monotherapy and uses thereof
US20230106174A1 (en) 2021-05-05 2023-04-06 Revolution Medicines, Inc. Ras inhibitors
EP4334325A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
EP4334318A4 (en) 2021-05-05 2025-03-05 Huyabio International, LLC COMBINATION THERAPIES WITH SHP2 INHIBITORS AND PD-1 INHIBITORS
CN117177752A (zh) 2021-05-05 2023-12-05 诺华股份有限公司 用于治疗mpnst的化合物和组合物
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
CN117642166A (zh) 2021-06-09 2024-03-01 中外制药株式会社 用于癌症治疗的组合疗法
WO2022258600A1 (en) 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
EP4368614A4 (en) * 2021-07-07 2025-07-09 Hinova Pharmaceuticals Inc SYNTHESIS AND USE OF PHOSPHATASE DEGRADING AGENT
AU2022336415A1 (en) 2021-09-01 2024-01-04 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
JP2024539852A (ja) 2021-11-04 2024-10-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のためのキナゾリノン化合物の新規使用
TW202342040A (zh) 2022-02-21 2023-11-01 瑞士商諾華公司 藥物配製物
CN114524772B (zh) * 2022-02-28 2023-07-11 中国药科大学 一种含杂环串联类化合物及其制备方法与应用
EP4489755A1 (en) 2022-03-08 2025-01-15 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN116903581A (zh) * 2022-04-14 2023-10-20 山东大学 Shp2/hdac双靶点抑制剂及其制备方法和应用
AU2023285116A1 (en) 2022-06-10 2024-12-19 Revolution Medicines, Inc. Macrocyclic ras inhibitors
EP4568956A1 (en) 2022-08-11 2025-06-18 Relay Therapeutics, Inc. Solid forms of a cdk inhibitor
EP4345101A1 (en) 2022-09-29 2024-04-03 Irbm S.P.A. Azole derivatives as shp2 inhibitors
AU2023380159A1 (en) 2022-11-18 2025-05-15 Novartis Ag Pharmaceutical combinations and uses thereof
WO2024113194A1 (en) * 2022-11-30 2024-06-06 Canwell Biotech Limited Shp2 inhibitors, compositions and methods thereof
WO2024126660A1 (en) 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
AU2024243852A1 (en) 2023-04-07 2025-11-06 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
TW202448897A (zh) 2023-04-14 2024-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
WO2024218632A1 (en) 2023-04-17 2024-10-24 Array Biopharma Inc. Erk protein kinase inhibitors
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025034919A1 (en) 2023-08-08 2025-02-13 Quanta Therapeutics, Inc. Combination therapies with kras modulators
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025106901A1 (en) 2023-11-17 2025-05-22 Quanta Therapeutics, Inc. Combination cancer therapies with a kras modulator and an rtk-mapk pathway inhibitor
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025215527A2 (en) 2024-04-10 2025-10-16 Novartis Ag Pharmaceutical combinations and uses thereof
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
CN119039223B (zh) * 2024-10-31 2025-02-25 江苏豪森药业集团有限公司 一种含氮杂芳类衍生物的制备方法及其中间体
CN119661551B (zh) * 2024-12-16 2025-11-25 重庆大学 一种(3r,4s)-3-甲基-2-氧杂-8-氮杂螺[4.5]癸烷-4-胺盐酸盐的制备方法

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
EP0090505B1 (en) 1982-03-03 1990-08-08 Genentech, Inc. Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it
US4512991A (en) * 1982-12-27 1985-04-23 Merck & Co., Inc. 3-Acyl-2-amino-5-halo-6-(substituted)pyrazine antimicrobial compounds
FR2567518B1 (fr) 1984-07-11 1987-11-13 Sanofi Sa Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
DE3752141T2 (de) 1986-02-24 1998-03-26 Mitsui Petrochemical Ind Mittel zur behandlung von neuropathie
US5266573A (en) 1989-08-07 1993-11-30 Elf Sanofi Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9012316D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
DK169008B1 (da) 1990-06-01 1994-07-25 Holec Lk A S Fremgangsmåde og skærm til afskærmning af en strømtransformer samt strømtransformer med en sådan afskærmning
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
CA2263129C (en) 1996-08-16 2007-01-09 Schering Corporation Mammalian cell surface antigens; related reagents
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
MA26473A1 (fr) 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.
AU1102399A (en) 1997-10-21 1999-05-10 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
EP1053321A1 (en) 1998-02-09 2000-11-22 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
WO2000059893A1 (en) 1999-04-06 2000-10-12 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
ES2295040T3 (es) 1999-07-12 2008-04-16 Genentech, Inc. Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor.
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
CA2463989C (en) 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
WO2003064383A2 (en) 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof
MXPA04007697A (es) 2002-02-06 2004-11-10 Vertex Pharma Compuestos de heteroarilo utiles como inhibidores de gsk-3.
HRP20040800B1 (en) 2002-03-05 2012-11-30 Merck Frosst Canada & Co Axys Cathepsin cysteine protease inhibitors
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
GB0300783D0 (en) 2003-01-14 2003-02-12 Btg Int Ltd Treatment of neurodegenerative conditions
EP1603901B1 (en) * 2003-03-07 2008-10-15 MERCK SHARP & DOHME LTD. Tetrahydropyran compounds as tachykinin antagonists
JP4638876B2 (ja) 2003-05-23 2011-02-23 ワイス Ｇｉｔｒリガンド及びｇｉｔｒリガンド関連分子及び抗体及びその使用
WO2005007190A1 (en) 2003-07-11 2005-01-27 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
JP2007518399A (ja) 2003-12-02 2007-07-12 ジェンザイム コーポレイション 肺癌を診断および治療する組成物並びに方法
EP1737841A1 (en) 2004-04-01 2007-01-03 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists
JP5213229B2 (ja) * 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
KR20180122750A (ko) 2004-09-02 2018-11-13 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
KR20070095952A (ko) 2004-12-16 2007-10-01 버텍스 파마슈티칼스 인코포레이티드 염증성 질환, 증식성 질환 및 면역학적으로 매개된 질환치료용 Ｔｅｃ 계열 단백질 키나제의 억제제로서 유용한피리드-2-온
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
KR20080043840A (ko) 2005-09-13 2008-05-19 팔라우 파르마 에스에이 히스타민 ｈ4 수용체 활성의 조정자로서 2-아미노피리미딘유도체
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
EP1981969A4 (en) 2006-01-19 2009-06-03 Genzyme Corp ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
WO2007112368A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
DK2041071T3 (da) 2006-06-29 2014-09-01 Kinex Pharmaceuticals Llc Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade
US7515405B2 (en) 2006-07-25 2009-04-07 Hewlett-Packard Development Company, L.P. Anti-rotation mechanism for an electronic device
US20090137549A1 (en) 2006-11-09 2009-05-28 Paul John Edward Novel compounds useful for the treatment of degenerative & inflamatory diseases
WO2008100412A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperidine derivatives
DK2137162T3 (en) * 2007-03-15 2018-11-26 Novartis Ag Organic compounds and their applications
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
AU2008275589B2 (en) 2007-07-12 2013-11-21 Gitr, Inc. Combination therapies employing GITR binding molecules
PE20090678A1 (es) 2007-09-12 2009-06-27 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
BRPI0907718A2 (pt) 2008-02-11 2017-06-13 Curetech Ltd método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
EP2271631B1 (en) 2008-04-22 2018-07-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EP2310381A1 (en) 2008-06-13 2011-04-20 Novartis AG 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
CN102203074A (zh) 2008-06-20 2011-09-28 麦它波莱克斯股份有限公司 芳基gpr119激动剂及其用途
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
GB0812031D0 (en) 2008-07-01 2008-08-06 7Tm Pharma As Thiazole derivatives
CA2729810A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Tgf-.beta. antagonist multi-target binding proteins
US9174969B2 (en) 2008-07-21 2015-11-03 University Of South Florida Indoline scaffold SHP-2 inhibitors and cancer treatment method
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP2350129B1 (en) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
US8586023B2 (en) 2008-09-12 2013-11-19 Mie University Cell capable of expressing exogenous GITR ligand
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2370424A1 (en) * 2008-11-10 2011-10-05 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
TW202442680A (zh) 2008-12-09 2024-11-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
CN102356066A (zh) 2008-12-10 2012-02-15 同和药品株式会社 新型2，6-取代的-3-硝基吡啶衍生物、其制备方法及包含有其的药物组合物
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2010121212A2 (en) 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Indoline scaffold shp-2 inhibitors and method of treating cancer
CN108752280A (zh) 2009-08-17 2018-11-06 纪念斯隆-凯特琳癌症中心 热休克蛋白结合化合物、组合物以及其制备和使用方法
IN2012DN01920A (cg-RX-API-DMAC7.html) 2009-09-03 2015-07-24 Schering Corp
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
US8673913B2 (en) 2009-11-13 2014-03-18 Case Western Reserve University SHP-2 phosphatase inhibitor
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
WO2011090762A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
WO2012002577A1 (ja) 2010-06-30 2012-01-05 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
JP2013531037A (ja) 2010-07-13 2013-08-01 メルク・シャープ・エンド・ドーム・コーポレイション スピロ環式化合物
ES2823350T3 (es) 2010-07-29 2021-05-06 Rigel Pharmaceuticals Inc Compuestos heterocíclicos que activan AMPK y métodos de uso de los mismos
WO2012027495A1 (en) * 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
EP2630134B9 (en) 2010-10-20 2018-04-18 Pfizer Inc Pyridine-2- derivatives as smoothened receptor modulators
AU2011344001B2 (en) 2010-12-13 2016-06-30 Array Biopharma Inc. Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
JP5727276B2 (ja) 2011-03-04 2015-06-03 協同油脂株式会社 グリース組成物及びグリース封入転がり軸受
HUE034979T2 (en) 2011-09-12 2018-05-02 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
MX349096B (es) 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
WO2013096093A1 (en) 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors
KR20150016406A (ko) 2012-06-07 2015-02-11 에프. 호프만-라 로슈 아게 탄키라제의 피라졸로피리미돈 및 피라졸로피리돈 억제제
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014054053A1 (en) 2012-10-03 2014-04-10 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof
WO2014160521A1 (en) * 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
US10189859B2 (en) 2013-12-21 2019-01-29 Nektar Therapeutics Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN105899491B (zh) 2014-01-17 2019-04-02 诺华股份有限公司 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物
JP6473457B2 (ja) 2014-01-17 2019-02-20 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物
HRP20220096T1 (hr) 2014-05-01 2022-04-15 Celgene Quanticel Research, Inc. Inhibitori lizin specifične demetilaze-1
US10174032B2 (en) 2014-05-05 2019-01-08 Signalrx Pharmaceuticals, Inc. Heterocyclic compound classes for signaling modulation
EP3310771B1 (en) 2015-06-19 2020-07-22 Novartis AG Compounds and compositions for inhibiting the activity of shp2
ES2741746T3 (es) 2015-06-19 2020-02-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
JP6718889B2 (ja) 2015-06-19 2020-07-08 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
WO2017156397A1 (en) 2016-03-11 2017-09-14 Board Of Regents, The University Of Texas Sysytem Heterocyclic inhibitors of ptpn11
JP7044375B2 (ja) 2016-05-31 2022-03-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｐｔｐｎ１１の複素環式阻害剤
KR20230109185A (ko) 2016-06-07 2023-07-19 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
TN2019000010A1 (en) 2016-07-12 2020-07-15 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
TWI848901B (zh) 2016-10-24 2024-07-21 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
EP3568204B1 (en) 2017-01-10 2023-08-30 Novartis AG Pharmaceutical combination comprising an alk inhibitor and an shp2 inhibitor
CA3051054A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
CA3051206A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Bicyclic compounds as allosteric shp2 inhibitors
PT3601239T (pt) 2017-03-23 2024-10-24 Jacobio Pharmaceuticals Co Ltd Novos derivados heterocíclicos úteis como inibidores de shp2
AU2018328273A1 (en) 2017-09-07 2020-03-12 Revolution Medicines, Inc. SHP2 inhibitor compositions and methods for treating cancer
EP3687997A1 (en) 2017-09-29 2020-08-05 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
RU2020115095A (ru) 2017-10-12 2021-11-12 Революшн Медсинз, Инк. Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2
MX2020006273A (es) 2017-12-15 2020-09-14 Revolution Medicines Inc Compuestos policiclicos como inhibidores alostericos de shp2.
US20200392161A1 (en) 2018-02-21 2020-12-17 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
AU2019240299B2 (en) 2018-03-21 2023-06-22 D.E. Shaw Research, Llc SHP2 phosphatase inhibitors and methods of use thereof
JP2021521155A (ja) 2018-04-10 2021-08-26 レヴォリューション・メディスンズ，インコーポレイテッド Ｓｈｐ２阻害剤組成物、癌を処置するための方法、およびｓｈｐ変異を有する対象を特定するための方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021130662A (ja) * 2015-06-19 2021-09-09 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
JP7146016B2 (ja) 2015-06-19 2022-10-03 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物

Also Published As

Publication number Publication date
ES2695242T3 (es) 2019-01-02
MA39282A1 (fr) 2018-06-29
AR100033A1 (es) 2016-09-07
AU2015207757B2 (en) 2017-04-06
KR20160103137A (ko) 2016-08-31
AU2015207757A8 (en) 2017-05-11
US12209098B2 (en) 2025-01-28
PE20170011A1 (es) 2017-03-25
IL246436B (en) 2019-10-31
TN2016000268A1 (en) 2017-10-06
SI3094628T1 (sl) 2018-11-30
CY1121155T1 (el) 2020-05-29
BR112016016432A2 (cg-RX-API-DMAC7.html) 2017-08-08
PH12016501336B1 (en) 2019-05-17
DK3094628T3 (en) 2018-12-03
PH12016501336A1 (en) 2016-08-15
MX356895B (es) 2018-06-19
TWI657083B (zh) 2019-04-21
MY176357A (en) 2020-08-03
US20200181168A1 (en) 2020-06-11
US20220396585A1 (en) 2022-12-15
CU24424B1 (es) 2019-06-04
US20180201623A1 (en) 2018-07-19
CR20200617A (es) 2021-02-11
BR112016016432B1 (pt) 2022-11-29
DOP2016000177A (es) 2016-09-30
TW201612170A (en) 2016-04-01
AP2016009299A0 (en) 2016-06-30
PT3094628T (pt) 2018-11-21
HUE039869T2 (hu) 2019-02-28
ECSP16067692A (es) 2017-10-31
CA2935695A1 (en) 2015-07-23
AU2015207757B8 (en) 2017-05-11
KR102688024B1 (ko) 2024-07-25
JP2017502993A (ja) 2017-01-26
CA2935695C (en) 2022-08-30
RS57757B1 (sr) 2018-12-31
GT201600147A (es) 2018-11-27
KR102501558B1 (ko) 2023-02-20
MX2016009223A (es) 2016-10-05
US11952386B2 (en) 2024-04-09
HRP20181832T1 (hr) 2019-01-11
US10336774B2 (en) 2019-07-02
KR20230028581A (ko) 2023-02-28
EA031573B1 (ru) 2019-01-31
NZ721598A (en) 2018-08-31
US20210371429A1 (en) 2021-12-02
SG11201605272SA (en) 2016-08-30
NI201600101A (es) 2016-09-06
MA39282B1 (fr) 2018-10-31
AU2015207757A1 (en) 2016-07-07
EA201691442A1 (ru) 2016-12-30
CN105916845B (zh) 2019-11-12
PL3094628T3 (pl) 2019-01-31
US10968235B2 (en) 2021-04-06
WO2015107495A1 (en) 2015-07-23
EP3094628B1 (en) 2018-08-08
JO3517B1 (ar) 2020-07-05
US20220073537A1 (en) 2022-03-10
US20170015680A1 (en) 2017-01-19
SV2016005245A (es) 2016-11-21
CL2016001790A1 (es) 2016-12-30
CN105916845A (zh) 2016-08-31
EP3094628A1 (en) 2016-11-23
UY35957A (es) 2015-08-31
US10077276B2 (en) 2018-09-18
IL246436A0 (en) 2016-08-31
LT3094628T (lt) 2018-10-25
CR20160328A (es) 2016-11-10

Similar Documents

Publication Publication Date Title
US11952386B2 (en) N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
JP7278359B2 (ja) Ｓｈｐ２の活性を阻害するための化合物および組成物
JP6523303B2 (ja) Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物
JP6473457B2 (ja) Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物
EP3310774B1 (en) Compounds and compositions for inhibiting the activity of shp2
JP2018517746A (ja) Ｓｈｐ２の活性を阻害するための化合物および組成物
HK1228375A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
HK1228375B (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180115

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190514

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190528

R150 Certificate of patent or registration of utility model

Ref document number: 6534389

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250